Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24-week, randomized study by G Moyle et al.
POSTER PRESENTATION Open Access
Switching from Kivexa + efavirenz to Atripla reduces
total cholesterol in hypercholesterolemic subjects:
final results of a 24-week, randomized study
G Moyle1*, C Orkin2, M Fisher3, J Anderson4, J Dhar5, MH Wang6, J Ewan7
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Background
Dyslipidemia in persons with HIV contributes signifi-
cantly to cardiovascular (CV) risk. Abacavir (ABC) has
been shown to increase lipid levels and some cohort stu-
dies have suggested an association between ABC use
and myocardial infarction (MI). Comparative data sug-
gested Truvada (TDF/FTC) has a lesser effect on lipid
parameters than Kivexa [KVX]. We investigated the
change in fasting lipid parameters in hypercholesterole-
mic subjects switching from KVX + Efavirenz [EFV] to
Atripla [ATR].
Methods
A 24-week, UK, open-label study in subjects stable on
once daily (QD) KVX+EFV, HIV RNA <50 copies/mL
for ≥6 months and fasting total cholesterol [TC] ≥5.2
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mmol/L at screening, randomized to continue KVX
+EFV or switch to QD ATR. The primary endpoint was
change from baseline to Week 12 in fasting TC.
Changes in fasting lipid parameters and 10 year risk
score for coronary heart disease (CHD) were also
assessed. At Week 12 subjects continuing on KVX+EFV
were switched to ATR (delayed switch to ATR) and all
subjects received ATR until Week 24.
Results
157 randomized subjects received at least 1 dose of
study medication; 78 continued KVX+EFV, 79 switched
to ATR at baseline; 69 switched to ATR at Week 12.
Subjects were well matched for baseline characteristics.
Figure 1.
At 12 weeks there was a significant reduction in TC,
LDL, HDL and TG in the ATR arm (p<0.001) and the
ATR vs KVX+EFV between group difference (p<0.001),
which was confirmed for TC, LDL and HDL in the
delayed switch to ATR arm after 12 weeks of switch.
The mean (SD) change in 10-year risk for CHD was
-0.6 (3.85) ATR vs -0.1 (2.69) KVX+EFV at Week 12
and -0.1 (3.68) in the delayed switch to ATR arm after
12 weeks of switch. There were no protocol defined vir-
ologic failures and no study drug related SAEs.
Conclusion
Switching from KVX+EFV to ATR led to a significant,
rapid decline in lipid parameters and this may have had
a positive impact on calculated CHD risk while main-
taining virologic suppression. The full study results
showed that the initial 12 week results were replicated
in the delayed switch to ATR arm. These results con-
firm that ATR is a preferred treatment option to a KVX
based regimen in hypercholesterolemic patients.
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